+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

NGLY1 Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

NGLY1 Deficiency - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Von Hippel-Lindau Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Von Hippel-Lindau Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Craniopharyngioma - Pipeline Insight, 2025 - Product Thumbnail Image

Craniopharyngioma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
5-HT1 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 90 Pages
  • Global
From
5-HT2 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2 Agonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
5-HT4 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT4 Agonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 120 Pages
  • Global
From
5-HT4 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT4 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Tardive Dyskinesia - Pipeline Insight, 2025 - Product Thumbnail Image

Tardive Dyskinesia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Relapsing Multiple Sclerosis (RMS) - Pipeline Insight, 2025 - Product Thumbnail Image

Relapsing Multiple Sclerosis (RMS) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hepatic Encephalopathy - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatic Encephalopathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dystonia - Pipeline Insight, 2025 - Product Thumbnail Image

Dystonia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Seizures - Pipeline Insight, 2025 - Product Thumbnail Image

Seizures - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Insight, 2025 - Product Thumbnail Image

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Postherpetic Neuralgia - Pipeline Insight, 2025 - Product Thumbnail Image

Postherpetic Neuralgia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 65 Pages
  • Global
From
Myasthenia Gravis- Pipeline Insight, 2025 - Product Thumbnail Image

Myasthenia Gravis- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Spinal Muscular Atrophy - Pipeline Insight, 2025 - Product Thumbnail Image

Spinal Muscular Atrophy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Spasticity - Pipeline Insight, 2025 - Product Thumbnail Image

Spasticity - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 106 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more